Related Experiment Video
Updated: Aug 1, 2025

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
Probiotics in IBS: A Treatment Boon or a Pill Bulk: RCT-based Analysis
1Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Introduction:
Irritable Bowel Disease is a functional Gastro-intestinal disorder that is characterised by chronic abdominal pain, and altered bowel habit unexplained by the organic cause.[1] Probiotics are live micro organisms that are intended to extend health benefits when consumed generally by improving gut microbiota.[2] The role of probiotics continues to be controversial in IBS. Here we are presenting a RCT based report of role of probiotics in IBS.
Materials:
This is a single blinded RCT done on 72 cases of Irritable Bowel syndrome including 31 diarrhoea and 23 constipation predominant and 18 mixed manifestation. A drug containing probiotics organisms chiefly Lactobacillus, Bifidobacterium and Streptococcus species was used against a placebo capsule containing inert powdered salt. A results were analysed using MS excel and medical softwares, SPSS and Medcalc.
Result:
Out of 36 pt in study groups 29 shows improvement among which 18 shows significant relief in symptoms. Relief in symptoms was transient. About 40% reported re-appearance of symptoms within 4 weeks of discontinuation of drug. Among the placebo group 9 out of 36 patients reported relief, and difference in results were statistically significant. Improvement in symptoms was seen in all the groups with varying degree of relief with maximum benefit in diarrhoea predominant group.
Conclusion:
Although the origin of disease is functional there is a significant relief with probiotics. Probiotics are boon in treatment rather than financial burden on exhausted and frustrated patients who seeks relief for a better quality of life. References Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147(5):1149-1172.e2. Shi LH, Balakrishnan K, Thiagarajah K, et al. Beneficial properties of probiotics. Trop Life Sci Res 2016;27(2):73-90.
More Related Videos
Related Concept Videos
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome III: Medical and Nursing Management

